Abstract Library
Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.
Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.
ENETS Abstract Search
Introduction: Somatostatin receptor 2 (SST2) is an established target for the treatment of NETs and potentially other solid tumours.
Conference:
Presenting Author:
Authors: Zhao J, Sturchler E, Yang B, Chen M, Tang Y,
Keywords: somatostatin, solid tumour, drug conjugate, internalisation, cytotoxicity,
#4345 Real-life results of the treatment with lutetium in advanced neuroendocrine tumours
Introduction: Therapy using lutetium-177 dotatate (177LU) was approved in Europe in 2017 for the treatment of advanced neuroendocrine tumours (NETs). Since then, it has become part of the strategies for treating NETs, making it now possible to evaluate real-life results.
Conference:
Presenting Author: Campos Ramírez S
Authors: Campos Ramírez S, Andrés A, Gómez Mugarza P, Blanco Abad C, Monreal Cepero M,
Keywords: Neuroendocrine tumour, Lutetium, Efficacy, Toxicity, Real-Word Evidence,
Introduction: Everolimus 10mg PO daily is approved for patients (pts) with advanced G1/G2 neuroendocrine tumours (NET) but is associated with significant toxicity, including 20% of serious infections in real-world pts. In phase I trials, 5mg/day was sufficient to inhibit the mTOR pathway. Retrospective data suggest that 5mg/day is similarly effective to 10mg/day but less toxic.
Conference:
Presenting Author:
Authors: Riechelmann R, Campos A, Durant L, Bulzico D,
Keywords: everolimus, neuroendocrine tumour, dose optimisation, toxicity,
#4208 The somatostatin system – A silent messenger in pheochromocytomas and paragangliomas?
Introduction: Pheochromocytomas and paragangliomas (PPGLs) are rare neuroendocrine neoplasms (NENs) arising from neural crest-derived chromaffin cells. Due to the abundance of somatostatin receptors (SSTs) on the surface of most NENs, somatostatin analogues (SSAs) have become a cornerstone in their diagnosis and treatment. However, while PPGLs exhibit this feature, their functional responsiveness to SSAs remains limited, with the underlying cause of this resistance being still elusive.
Conference:
Presenting Author:
Authors: García Vioque V, Moreno-Montilla M, Blázquez-Encinas R, Barlier A, Arroba E,
Keywords: pheochromocytomas, paragangliomas, neuroendocrine tumor, somatostatin analogues, treatment resistance,
Introduction: Epidemiological data on GEP-NEN are heterogeneous, making interpretation difficult.
Conference:
Presenting Author:
Authors: Panzuto F, Partelli S, Campana D, Pusceddu S, Spada F,
Keywords: Neuroendocrine tumor, epidemiology, registry, management, database,